A61 mg, resulting in ~25% greater 24-hour urinary glucose excretion. In addition, CANA 300 mg may transiently block intestinal SGLT1, delaying glucose absorption and reducing postprandial glucose. METHODS: The IMS CORE Diabetes Model was used to evaluate the cost-effectiveness of CANA 100 and 300 mg versus DAPA 10 mg using Spanish-specific utilities and cost data. Direct costs were reported in euros and an annual discount rate of 3% was applied to costs and effects. The time horizon used for the economic evaluation was 40 years to reflect the chronic nature of the disease. A randomised, controlled trial of CANA in dual therapy and an NMA were sourced for initial patient characteristics and treatment effects. Results were compared with the willingness-to-pay (WTP) threshold reported for Spain (€ 30,000/QALY). RESULTS: CANA 100 mg dominated DAPA in dual therapy, with 0.061 quality-adjusted life years (QALYs) gained. CANA 300 mg was cost-effective compared to DAPA 10 mg in dual therapy with a cost-effectiveness ratio below the WTP threshold in Spain; QALYs gained were 0.084. CONCLUSIONS: These results suggest that adding CANA 100 or 300 mg instead of DAPA 10 mg in patients inadequately controlled on metformin would result in more efficient use of healthcare resources in the Spanish setting.

No abstract

To conduct a cost-utility evaluation of dabigatran etexilate compared with enoxaparin for the prevention of venous thromboembolism (VTE) after total knee replacement (TKR) and total hip replacement (THR) in Colombia. METHODS: An acute phase model, using decision analysis, and a long-term simulation Markov model were developed to compare the clinical outcomes, utilities, and direct medical costs of dabigatran 220 mg once daily and subcutaneous enoxaparin 40 mg once daily for VTE prophylaxis after TKR or THR. Time frame for the acute inpatient-phase was 14 days for TKR and 30 days for THR; adjustments for adverse events and average length of hospital stay were performed. The long-term simulation was performed using 6-months cycle transitions to eight health states for both TKR and THR. Transition probabilities for VTE and bleeding events were derived from Phase III studies comparing the two treatments. The probabilities of long-term events were estimated using data from published longitudinal studies. The payer perspective for a lifetime horizon was used. Sensitivity analyses were performed to assess the model robustness. The annual discount rate was set at 3.

The use of administrative datasets can be a useful tool in cancer surveillance by providing disease patterns, utilization of services, and patient characteristics. This study explores characteristics of treatment and staging among lung cancer patients in the US using hospital-based services. METHODS: A crosssectional study of chemotherapy treated lung cancer patients receiving in or outpatient services from hospitals in MedAssets' health data from July 1, 2010 to June 30, 2011 were assessed for staging and treatment characteristics. The Thomas, et al. staging algorithm was applied to patient services to estimate stage of lung cancer. Descriptive statistics were calculated for the sample by stage, treatment characteristics, procedures and hospital characteristics. Patterns of care were tabulated and compared by cancer stage. RESULTS: The sample included 14,628 unique patients who received chemotherapy during the study period spanning over 217,000 hospital visits. The majority (75%) of hospital visits were classified as stage 1-2 compared to stage 3-4 (25%). Stage 1-2 patients experienced fewer hospital visits (5.9 vs. 12.5, p Ͻ0.0001) and had a significantly higher proportion of inpatient stays (22.1% vs. 6.7%, p Ͻ0.0001). Most visits (88.7%) occurred in hospitalbased outpatient facilities. There were 52,289 (3.1 visits per patient) chemotherapy related visits. Primary chemotherapies included: pemetrexed disodium (16.2 %), carboplatin (34.3%) and cisplatin (11.0%). Blood transfusions and other non-surgical procedures made up the largest portion (25.4%) of all procedures performed on both groups. Finally, both groups were treated in primarily in large (Ͼ300 beds, 75.1%), urban (90.1%), and teaching (59.1%) hospitals. CONCLUSIONS: The crosssectional analysis demonstrates the possible value of large-scale administrative data sets in illuminating differences in treatment characteristic in a chemotherapy-treated lung cancer population. Future analysis should evaluate the use of these data to help predict utilization and treatment patterns in larger populations.

OBJECTIVES:Biologic treatments had dramatically changed the therapeutics, outcomes and cost of management of psoriasis, a common chronic disease that strongly affects quality of life of patients. The aim of this study was to assess the cost-effectiveness of biologic alternatives currently available in Mexico for treatment of moderate to severe psoriasis from an institutional perspective. METHODS: A decision-tree model was developed to simulate the clinical course of patients treated with etanercept, adalimumab, infliximab or ustekinumab as first-line therapies, as well as treatment associated costs (2-year timeframe with a 5% annual discount rate). Effectiveness measures were the proportion of patients reaching 75% improvement in the Psoriasis Area and Severity Index (PASI-75) and quality adjusted life years gained (QALY=s). Costs considered included: biologics drugs, concomitant medication, medical follow-up and side effects management. Clinical response of alternatives was extracted from published literature, while unit costs were collected from Instituto Mexicano del Seguro Social (IMSS) official databases. Probabilistic sensitivity analyses were completed. RESULTS: After two years, the proportions of patients reaching PASI-75 were 59%, 62.1%, 62.7%, and 64.5% for adalimumab, etanercept, infliximab and ustekinumab, respectively (pϭ0.077, Friedman test); QALY=s associated to each alternative were: 1.5554, 1.5633, 1.5650 and 1.5695, respectively (pϭ0.392, Friedman test). Given that in the timeframe considered there are no differences between effectiveness of therapies, a costminimization rather than a cost-effectiveness analysis was performed.